Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer

You may be eligible if

• (1) Age ≥18 years at the time of signing informed consent, regardless of sex;(2) Able and willing to provide written informed consent, understand the study requirements, and comply with all study procedures and follow-up visits;(3) Histologically or cytologically confirmed recurrent or metastatic colorectal cancer, with EGFR-positive tumor expression confirmed by immunohistochemistry;(4) Previously received at least two lines of standard systemic therapy for recurrent or metastatic colorectal cancer;(5) At least one measurable lesion according to RECIST version 1.1, with a longest diameter ≥10 mm;(6) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, assessed within 7 days before the first dose;(7) Estimated life expectancy ≥12 weeks;(8) Adequate hematologic and organ function, without blood transfusion or use of cell growth factors within 14 days before the first dose: absolute neutrophil count ≥1.5 × 10\^9/L; platelet count ≥75 × 10\^9/L; hemoglobin ≥85 g/L; serum creatinine ≤1.5 times the upper limit of normal (ULN); AST and ALT ≤2.5 times ULN, or ≤5 times ULN in participants with liver metastases; total bilirubin ≤1.5 times ULN; and INR and activated partial thromboplastin time ≤1.5 times ULN, except in participants receiving anticoagulant therapy;(9) Women of childbearing potential must have a negative serum pregnancy test within 7 days before treatment. Women of childbearing potential and men with partners of childbearing potential must agree to use highly effective contraception from signing informed consent until 1 year after the last dose.